← Eichor
Study identifier: NCT06746194 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy

Condition: Hepatocellular Carcinoma (HCC)  ·  Sponsor: Ruijin Hospital

PhaseN/A
Planned participants40
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This study aims to investigate the value of 68Ga-FAPI PET/CT in the efficacy evaluation of advanced unresectable hepatocellular carcinoma patients undergoing systemic antitumor therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Jiajia Hu  ·  13524945287  ·  jiajiahu@shsmu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Ruijin Hospital affiliated to Shanghai Jiao Tong University of MedicineShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06746194